Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Indexing Status
Subject indexing assigned by CRD

MeSH
Angioplasty, Transluminal, Percutaneous Coronary; Argentina; Cost-Benefit Analysis; Drug-Eluting Stents; Humans; Sirolimus; Stents

AccessionNumber
22009102561

Date bibliographic record published
14/10/2009